NCT07278479 2026-04-08
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT06503146 2026-03-27
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07174583 2026-01-23
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
Phase 1/2 Recruiting
NCT05978284 2026-01-05
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07038096 2026-01-05
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06283719 2025-11-17
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT05652686 2025-09-23
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT06505824 2025-09-18
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting